Drugs / SIBP-A16
last change Jan 2026 re-read 2 minutes ago

SIBP-A16

Developed for
respiratory syncytial virus infectious disease
Investigated by
Shanghai Institute Of Biological Products

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07363837 Jan 2026 → Mar 2027 expected respiratory syncytial virus infectious disease Shanghai Institute Of Biological Products Not yet recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SIBP-A16 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07363837
Route Intramuscular “via intramuscular or intravenous injection” NCT07363837
Route Intravenous “via intramuscular or intravenous injection” NCT07363837